Amikacin (Inhalation) — Competitive Intelligence Brief

Amikacin (Inhalation) (Amikacin (Inhalation)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aminoglycoside antibiotic. Area: Infectious Disease.

marketed Aminoglycoside antibiotic Bacterial 30S ribosomal subunit Infectious Disease Small molecule

Target snapshot

Amikacin (Inhalation) (Amikacin (Inhalation)) — The University of Queensland. Amikacin is an aminoglycoside antibiotic that binds to bacterial ribosomes and inhibits protein synthesis, leading to bacterial cell death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amikacin (Inhalation) TARGET	Amikacin (Inhalation)	The University of Queensland	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Minocycline HCl	Minocycline HCl	OraPharma	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
inhaled tobramycin	inhaled tobramycin	Seattle Children's Hospital	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Oral doxycycline hyclate	Oral doxycycline hyclate	Galderma R&D	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Cefazolin + Gentamicin	Cefazolin + Gentamicin	Mercy Health Ohio	marketed	Beta-lactam antibiotic + aminoglycoside antibiotic combination	Bacterial penicillin-binding proteins (cefazolin); bacterial 30S ribosomal subunit (gentamicin)
Gentamicin - three days	Gentamicin - three days	Murdoch Childrens Research Institute	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Doxycycline Hyclate Enteric-Coated Capsules	Doxycycline Hyclate Enteric-Coated Capsules	The Third Xiangya Hospital of Central South University	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aminoglycoside antibiotic class)

1. U.S. Army Medical Research and Development Command · 2 drugs in this class
2. Hospital General Universitario Elche · 2 drugs in this class
3. Murdoch Childrens Research Institute · 2 drugs in this class
4. Public Health Service of Amsterdam · 1 drug in this class
5. Seattle Children's Hospital · 1 drug in this class
6. Shanghai Pulmonary Hospital, Shanghai, China · 1 drug in this class
7. Shanghai Zhongshan Hospital · 1 drug in this class
8. South Australian Health and Medical Research Institute · 1 drug in this class
9. The University of Queensland · 1 drug in this class
10. University of Leipzig · 1 drug in this class